0353 GMT - President Trump's "Liberation Day" tariffs are likely not a big concern for China's healthcare industry, Jefferies analysts say in a research note. Drugs and active pharmaceutical ingredients are exempt from tariffs, and even if Trump imposed any tariffs in the future, most Chinese biotech companies have U.S. partners that are not considered exporters, they say. Contract drug makers, such as the WuXi companies, are in exempt categories as well, they note. "If the exemption were canceled, the tariff would apply to all non-U.S. competitors, while Chinese players would retain cost and efficiency advantages," they say. Medical equipment makers are subject to 54% tariffs, but the analysts reckon the impact will be manageable, as the Chinese makers, such as Mindray Medical International, have low sales exposure to the U.S. (sherry.qin@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 23:53 ET (03:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.